{
    "nct_id": "NCT04320316",
    "official_title": "An Open Label Trial to Assess the Safety and Efficacy of KRN23, an Investigational Antibody to FGF23, in a Single Pediatric Patient With Epidermal Nevus Syndrome (ENS) and Associated Hypophosphatemic Rickets",
    "inclusion_criteria": "* Patient has confirmed ENS by physician diagnosis\n* Patient has confirmed FGF23 elevations in the context of low serum phosphorous < 4.1 mg/dL\n* Patient able to tolerate KRN23 treatment\n* Have a corrected serum calcium level < 10.8mg/dL\n* Have an eGFR >60 ml/min\n* Must be willing in the opinion of the investigator, to comply with study procedures and schedule\n* Provide written informed consent by a parent after\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 6 Months",
    "exclusion_criteria": "* Patient should not use CRYSVITA with Oral phosphate or active Vitamin D analogs.\n* Patient and investigator should not initiate CRYSVITA if Phosphorus level is within or above normal.\n* CRYSVITA is contraindicated in patients with severe renal impairment or end stage renal disease because these conditions are associated with abnormal mineral metabolism.\n* The use or enrollment in studies using other investigational therapies including other monoclonal antibodies\n* Subject and their Parent not willing or not able to give written informed consent\n* In the Investigators opinion, the subject may not be able to meet all the requirements for study participation\n* Subject has a history of hypersensitivity to KRN23 excipients that in the opinion of the investigator, places the subject at an increased risk of adverse effects\n* Subject has a condition that in the opinion of the investigator could present a concern for subject safety or data interpretation.",
    "miscellaneous_criteria": ""
}